Close this search box.

Venture report: Metsera’s $290M launch, Regeneron’s new VC fund

ARTICLE | Finance

Plus fundings for Asher, Pathios, Outrun and Theolytics

By Paul Bonanos, Director of Biopharma Intelligence, and Gunjan Ohri, Data Content Analyst

April 18, 2024 9:38 PM UTC

Backed by VCs at Arch and a team from The Medicines Co., obesity and metabolic disease start-up Metsera is developing a pipeline the company believes will be differentiated due to its therapies’ duration of effect, next-generation targets and combination approaches.

Arch Venture Partners and Population Health Partners (PHP) have launched Metsera Inc. with $290 million in initial funding, with the aim of developing best-in-class injectable and oral therapies for weight loss, obesity-related disorders and metabolic diseases. The latter firm was formed by former executives at The Medicines Co. in the wake of its 2019 acquisition by Novartis AG (SIX:NOVN; NYSE:NVS) for $9.7 billion…